Fragile X Syndrome, a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people suffering from it, is a result of mutation associated with the gene known as FMR1.
As per DelveInsight assessments, the market size of Fragile X Syndrome (FXS) in the 7MM was found to be USD 33.51 Million in 2017, for the study period, 2017–2028.
Top companies involved fuelling the FXS Market are:
Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others.
Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward.
Visit to gain access to our Newsletter: https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome
